Thiberville L, Payne P, Vielkinds J, LeRiche J, Horsman D, Nouvet G, Palcic B, Lam S
Institut National de la Santé et de la Recherche Medicale, Unité 295, Faculté de Medecine et de Pharmacie de Rouen, France.
Cancer Res. 1995 Nov 15;55(22):5133-9.
Human bronchial carcinoma is thought to develop through progressive stages from basal cell hyperplasia to squamous metaplasia, dysplasia, carcinoma in situ, and finally invasive cancer. In this study, we used tissue microdissection to examine loss of heterozygosity of chromosomes 3p21, 5q21, and 9p21 at each stage of the epithelial progression to invasive cancers. Forty-eight premalignant/malignant bronchial sites were biopsied from 13 patients (including 9 subjects without cancer) using fluorescence bronchoscopy. Eighteen sites with moderate/severe dysplasia in 6 patients were subjected to bronchoscopic and molecular follow-up during a 3-month to 2-year period. Seven separate cases of advanced non-small cell bronchial cancers were also analyzed. From the baseline biopsies, the prevalence of 3p and 9p deletions increased significantly from no deletion in the hyperplasia/metaplasia samples (n = 9) to 37 and 31% of the informative cases, respectively, in the dysplasia samples (n = 29), to 100 and 83%, respectively, for the carcinomas in situ (n = 6), and 100% in the invasive cancers (n = 11). Chromosome 5q deletion was significantly more frequent in invasive cancers (70% of the informative cases) as compared to carcinoma in situ (40%), dysplasias (33%), and hyperplasia/metaplasia samples (11%). The number of chromosome alterations also increased significantly from the lowest to the highest grade lesions, showing evidence of accumulation of genetic damage from one group to another. The molecular follow-up analysis showed that the same genomic alteration can persist in a given dysplastic bronchial area for several months or years, and that the persistence or the regression of the molecular abnormality is well correlated with the evolution of the disease on follow-up. Our results suggest that molecular analysis of bronchial biopsies obtained by fluorescence bronchoscopy may be a very useful means to study the natural history of preinvasive bronchial lesions and the outcome of interventions, such as with chemopreventive treatment.
人类支气管癌被认为是从基底细胞增生逐步发展到鳞状化生、发育异常、原位癌,最终发展为浸润性癌。在本研究中,我们使用组织显微切割技术,检查上皮细胞发展为浸润性癌各阶段中3p21、5q21和9p21染色体杂合性缺失情况。使用荧光支气管镜从13例患者(包括9例无癌受试者)身上获取了48个癌前/恶性支气管部位的活检样本。对6例患者中18个中度/重度发育异常部位在3个月至2年期间进行了支气管镜和分子随访。还分析了7例晚期非小细胞支气管癌的独立病例。从基线活检样本来看,3p和9p缺失的发生率从增生/化生样本(n = 9)中无缺失显著增加到发育异常样本(n = 29)中分别为37%和31%的有效病例,原位癌(n = 6)中分别为100%和83%,浸润性癌(n = 11)中为100%。与原位癌(40%)、发育异常(33%)和增生/化生样本(11%)相比,5q染色体缺失在浸润性癌中(70%的有效病例)更为常见。染色体改变的数量也从最低级病变到最高级病变显著增加,显示出遗传损伤从一组到另一组累积的证据。分子随访分析表明,相同的基因组改变可在给定的发育异常支气管区域持续数月或数年,并且分子异常的持续或消退与随访中疾病的进展密切相关。我们的结果表明,通过荧光支气管镜获得的支气管活检样本的分子分析可能是研究浸润前支气管病变自然史和干预结果(如化学预防治疗)的非常有用的手段。